Yea, the tone has changed a bit to something like trying to explain politely, but having to do so repeatedly to an audience that doesn't quite get it.
Are we there yet? Are we there yet?
Based on the uproar over a poster presentation that was never stated to be including a cut of current data, why would you commit a date. Some here might have apoplexy or a temper tantrum and injure themselves if the date got pushed out.
As others have said, the data is coming from multiple people, at multiple locations, who are really sick.
Data would be peer reviewed by multiple people, including independently. Given the Fast Track Designation fot Bile Tract, do you think Imugene will be rushing to appease the noisy children first, or having measured discussions with FDA, peers etc on progress, the data, and when its ready to be presented.
Whilst there are a lot of moving parts, this isn't an assembly line.
I reckon within this next 3 months there will be a flurry of news. Would be remiss not to have a crack at lifting the D options if the data is looking promising.
GLTA
IMU Price at posting:
9.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)